Therapeutic radionuclides: production and decay property considerations.

WA Volkert, WF Goeckeler, GJ Ehrhardt… - Journal of nuclear …, 1991 - europepmc.org
The development of effective therapeutic radiopharmaceuticals requires careful
consideration in the selection of the radionuclide. The in vivo targeting and clearance …

ICRU REPORT 96, dosimetry-guided radiopharmaceutical therapy

G Sgouros, WE Bolch, A Chiti… - Journal of the …, 2021 - journals.sagepub.com
The International Commission on Radiation Units and Measurements (ICRU), since its
inception in 1925, has had as its principal objective the development of internationally …

[PDF][PDF] MIRD pamphlet no. 17: the dosimetry of nonuniform activity distributions—radionuclide S values at the voxel level

WE Bolch, LG Bouchet, JS Robertson… - Journal of Nuclear …, 1999 - Soc Nuclear Med
The availability of quantitative three-dimensional in vivo data on radionuclide distributions
within the body makes it possible to calculate the corresponding nonuniform distribution of …

Biophysical aspects of Auger processes

KG Hofer - Acta Oncologica, 1996 - Taylor & Francis
Radionuclide decay by electron capture and/or internal conversion is accompanied by
complex atomic vacancy cascades and emission of low-energy electrons, resulting in a …

MIRD pamphlet no. 25: MIRDcell V2. 0 software tool for dosimetric analysis of biologic response of multicellular populations

B Vaziri, H Wu, AP Dhawan, P Du… - Journal of Nuclear …, 2014 - Soc Nuclear Med
Patients undergoing nuclear medicine procedures for cancer therapy are administered
radiopharmaceuticals that emit various types of radiation. Because radiation has differential …

Localized dose enhancement to tumor blood vessel endothelial cells via megavoltage X-rays and targeted gold nanoparticles: new potential for external beam …

RI Berbeco, W Ngwa, GM Makrigiorgos - International Journal of Radiation …, 2011 - Elsevier
PURPOSE: Tumor endothelial cell damage during radiation therapy may contribute
significantly to tumor eradication and treatment efficacy. Gold nanoparticles (AuNPs) …

MIRD pamphlet no. 27: MIRDcell V3, a revised software tool for multicellular dosimetry and bioeffect modeling

S Katugampola, J Wang, A Rosen… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Radiopharmaceutical therapy is growing rapidly. However, yet to be addressed is the
implementation of methods to plan treatments for circulating tumor cells, disseminated tumor …

[PDF][PDF] The MIRD perspective 1999

RW Howell, BW Wessels, R Loevinger… - Journal of Nuclear …, 1999 - Soc Nuclear Med
J NucĂ-Med 1999; 40: 38-1 OS iluclear medicine procedures provide valuable diagnostic
information and noninvasive approaches to therapy. However, as with any medical …

PARaDIM: a PHITS-based Monte Carlo tool for internal dosimetry with tetrahedral mesh computational phantoms

LM Carter, TM Crawford, T Sato, T Furuta… - Journal of Nuclear …, 2019 - Soc Nuclear Med
Mesh-type and voxel-based computational phantoms comprise the current state of the art for
internal dose assessment via Monte Carlo simulations but excel in different aspects, with …

Applying gold nanoparticles as tumor-vascular disrupting agents during brachytherapy: estimation of endothelial dose enhancement

W Ngwa, GM Makrigiorgos… - Physics in Medicine & …, 2010 - iopscience.iop.org
Tumor vascular disrupting agents (VDAs) represent a promising approach to the treatment of
cancer, in view of the tumor vasculature's pivotal role in tumor survival, growth and …